Type 2 diabetes mellitus-associated cognitive dysfunction: Advances in potential mechanisms and therapies

Neurosci Biobehav Rev. 2022 Jun:137:104642. doi: 10.1016/j.neubiorev.2022.104642. Epub 2022 Mar 30.

Abstract

Type 2 diabetes (T2D) and its target organ injuries cause distressing impacts on personal health and put an enormous burden on the healthcare system, and increasing attention has been paid to T2D-associated cognitive dysfunction (TDACD). TDACD is characterized by cognitive dysfunction, delayed executive ability, and impeded information-processing speed. Brain imaging data suggest that extensive brain regions are affected in patients with T2D. Based on current findings, a wide spectrum of non-specific neurodegenerative mechanisms that partially overlap with the mechanisms of neurodegenerative diseases is hypothesized to be associated with TDACD. However, it remains unclear whether TDACD is a consequence of T2D or a complication that co-occurs with T2D. Theoretically, anti-diabetes methods are promising neuromodulatory approaches to reduce brain injury in patients with T2D. In this review, we summarize potential mechanisms underlying TDACD and promising neurotropic effects of anti-diabetes methods and some neuroprotective natural compounds. Constructing screening or diagnostic tools and developing targeted treatment and preventive strategies would be expected to reduce the burden of TDACD.

Keywords: Cognitive dysfunction; Insulin resistance; Pathophysiological mechanisms; Therapeutic approaches; Type 2 diabetes.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain / diagnostic imaging
  • Cognition
  • Cognitive Dysfunction* / complications
  • Diabetes Mellitus, Type 2* / complications
  • Humans
  • Neurodegenerative Diseases*